Generalised myasthenia gravis (gMG) is a rare and chronic IgG-mediated autoimmune neuromuscular disease that causes fluctuating and unpredictable muscle weakness. Standard treatment of gMG has traditionally included symptomatic therapy with acetylcholine esterase inhibitors such as pyridostigmine and disease-modifying treatments including steroids, as well as steroid-sparing immunosuppressants and thymectomy.
In this issue
Rate this content's potential impact on patient outcomes
Average rating / 5. Vote count:
No votes so far! Be the first to rate this content.
Latest articles
All articles

